blogs

Men's Health Genomics Beyond Prostate Cancer

chandra.ambadipudi@clairlabs.ai (Chandra Ambadipudi) — Wed, 24 Jun 2026 12:35:33 GMT

Men's health has a measurement problem, and genomics is positioned to solve it. For decades, the conversation about male genomic risk has centered almost entirely on prostate cancer, while a far wider landscape of actionable markers has gone largely unexamined. For clinicians and diagnostic leads, this represents both a clinical gap and a medical affairs opportunity. This article reframes men's health genomics beyond the prostate, surveying cardiovascular, pharmacogenomic, hereditary cancer, fertility, and digital biomarker evidence that should inform contemporary male health screening.

Cut 60% Cost Per Sample with Cloud-native NGS

Pankaj Gaddam — Tue, 23 Jun 2026 12:58:50 GMT

High-throughput clinical genomics has reached an inflection point, and the operational data now favors migration. Around 69% of high-throughput clinical labs have moved to cloud-based storage and compute for next-generation sequencing as their primary environment, citing scalability and real-time accessibility. These labs typically achieve 30–60% lower cost per sample at scale. For lab directors, molecular pathologists, bioinformatics leads, cloud architects, and CIOs who are already convinced their pipeline needs to change, the question is no longer whether to modernize but how to do so without compromising compliance. This article examines the financial, reproducibility, and regulatory case for cloud-native NGS, and how cloud bioinformatics reshapes the economics of clinical sequencing.

Building De-biased Genomic Datasets for Global Populations

Shekhar Vemuri — Thu, 18 Jun 2026 13:08:51 GMT

Precision medicine promises treatments tailored to individual biology. That promise, however, rests on genomic data that overwhelmingly reflects one slice of humanity. A landmark quantifying representation across genome-wide association studies (GWAS), pharmacogenomics, clinical trials, and direct-to-consumer genetic testing reveals a persistent diversity gap.

The consequences are not abstract. Polygenic risk scores derived from European-centric datasets lose predictive accuracy when applied to African, South Asian, or Indigenous populations. Such groups collectively represent the global majority. Running parallel to this ancestral skew is a less visible but equally consequential blind spot: the near-total absence of gender-inclusive genomic data. A review in Contemporary Clinical Trials found that only 0.08% of published clinical-trial articles between 2018 and 2022 reported participation of transgender or non-binary patients. When entire communities are missing from the evidence base, the science built on that evidence cannot serve them.

This blog can help genomics teams, clinical trial patient recruitment leads, and public health program managers to devise systematic strategies for building de-biased genomic data pipelines—from cohort design through computational modeling.

Agentic AI in Clinical Trials: From Experiment to Execution

Shashidhar Gururao — Wed, 17 Jun 2026 13:47:40 GMT

Clinical trial complexity is escalating on every measurable axis. Protocol design variables are trending upward across Phase II and Phase III studies. A recent study found that Phase III trials now average nearly 6 million data points each, a figure that has roughly tripled over the past decade. Between 2020 and 2024, average clinical trial cycle times increased by 14 months, even as the intervals between individual trials shortened by seven months.

The financial exposure compounds this operational strain. Each day of delay costs sponsors approximately $40,000 in direct trial costs, while unrealized drug sales amount to $500,000 per day. Speaking of protocol amendments, 76% of Phase I–IV trials require at least one; each adds an average of three months and up to $535,000 in additional expense.

The Copilot era of generative AI offered promising tools for content generation and data summarization. But it required constant human intervention. Clinical operations leaders, CRO heads, and trial sponsors evaluating how autonomous AI workflows reshape trial execution and ROI now need something more: systems that act, not just advise. This is where agentic AI clinical trials technology comes into play.

AI-ready Multi-omics Data Lakes for Biomarker Discovery

Amit Parhar — Mon, 15 Jun 2026 13:54:05 GMT

Modern drug development generates staggering volumes of molecular data. Genomic repositories such as GenBank and the Sequence Read Archive now hold more than 100 petabytes of sequencing information, a figure projected to surpass 2.5 exabytes. Yet sheer volume has not translated into proportional therapeutic insight. Translational teams still spend weeks reconciling proteomic, transcriptomic, and metabolomic outputs locked in disconnected silos. Each is governed by its own schema, quality threshold, and access protocol.

The stakes are clear. Around 150 senior biopharma executives were surveyed, and 77% of organizations already use real-world data (RWD) in drug development, while 93% believe AI can make that data more accessible and impactful. Meanwhile, another leading consultancy reports that 80% of surveyed executives expect GenAI to significantly reshape evidence generation within the next 12 months. The ambition is there. What is missing is the data architecture to match it.

This is where the concept of a multi-omics data lake becomes essential. Through this blog, we appeal to Heads of Bioinformatics, Translational scientists, Biomarker discovery leads, Computational biologists, and Precision medicine experts to lean towards the foundational infrastructure for AI-powered biomarker discovery platforms for biopharma.

How GenAI Is Transforming Translational Research

Amit Parhar — Thu, 11 Jun 2026 05:35:53 GMT

Translational research sits at the critical junction between laboratory discovery and clinical application. It is also one of the most time-intensive phases in drug development. The average journey from IND filing to FDA submission takes roughly 90 months for approved drugs. A recent drug development study also cites that Phase II trials alone average 30 months, an 11% increase over the previous decade.

Besides operational headaches, these delays also translate into staggering costs. Tufts CSDD data shows that each day of delay costs sponsors approximately $40,000 in direct trial expenses and up to $500,000 in unrealized drug sales. For research teams racing to move promising compounds into patients’ hands, the need for speed has never been more urgent.

Enter generative AI in drug discovery, a class of technologies now reshaping how scientists form hypotheses, interpret complex datasets, and compress the translational timeline. This blog is our attempt to illuminate the needs of translational leads, research scientists, and R&D decision-makers as they navigate the next frontier of drug discovery.

AI-Driven Recruitment for Women’s Health Clinical Trials

chandra.ambadipudi@clairlabs.ai (Chandra Ambadipudi) — Mon, 25 May 2026 10:37:59 GMT

Women’s health has become a high-priority topic in research and policy, but trial design still lags behind the need. Women’s health trials still face a representation problem. A 2024 study reaffirmed that women remain underrepresented in medical device trials, and a 2025 JAMA Network Open study noted that women remain underrepresented across several major trial areas, including cardiology, surgery, emergency medicine, and oncology. That weakens the generalizability of evidence and slows the development of treatments that truly reflect women’s needs.

For sponsors, this is not just a matter of fairness. It is a feasibility issue. When women’s health clinical trials struggle to recruit the right patients, timelines slip, screen failures rise, and the resulting dataset becomes harder to use commercially or clinically. That is why data-driven recruitment is now central to trial strategy rather than a support function.

Agentic AI for Bioinformatics Teams

Pankaj Gaddam — Fri, 22 May 2026 13:54:34 GMT

Life sciences teams do not need another dashboard. They need a better way to move work. That is why agentic AI in life sciences is starting to matter. A leading consultancy firm’s 2025 analysis found that 75% to 85% of workflows in pharma and medtech contain tasks that could be automated or augmented by agents. Such automations could also free up to 25% to 40% of organizational capacity. Leaders must view workflows with a fresh lens – agentic AI acts less like a tool and more like a conductor coordinating the work of many specialized agents.

How AI-Powered Diagnostics Are Transforming Women’s Health

Amit Parhar — Mon, 18 May 2026 13:31:22 GMT

Women’s health month should be more than a visibility moment. It should compel leaders to think about a harder question: why do so many diagnostic pathways still treat women’s health as a variation of the norm, when the evidence says otherwise? The World Economic Forum’s 2024 study on women’s health gap cites that women spend 25% more of their lives in poor health than men. Closing that gap could add at least $1 trillion a year to the global economy by 2040. That makes this a public health issue, but also a productivity, innovation, and growth issue.

The real opportunity is bigger than awareness. Present times call for a precision women’s health reset powered by AI-powered diagnostics, genomics in women’s health, and connected clinical intelligence to support earlier detection, better risk stratification, and more personalized follow-up. Nature’s 2024 collection on AI in women’s health, reproductive health, and maternal care reflects how quickly the field is moving from theory to implementation.

How AI-Powered Diagnostics Are Transforming Women’s Health

Shashidhar Gururao — Thu, 14 May 2026 12:53:10 GMT

Recruitment remains the weakest link in any clinical trial.

For all the industry talk about digital transformation, clinical trial patient recruitment still breaks more programs than most teams care to admit. The problem is not abstract. In 2024, almost 38% of sites identified trial complexity as a top challenge in an ACRP survey. Another report found the problem is even sharper for smaller sites, where 39% cited recruitment and retention as a major issue.

That is why recruitment is no longer a site-only issue. It is a system issue. Sponsors, CROs, and site networks need data-driven recruitment strategies that combine feasibility, population intelligence, and operational visibility before the first patient is screened.